Home page / Annual Meetings & Training / Annual Meetings / Annual Meeting 2015 / Fellows Speed Presentations / Modulating GPCRs’ Biological Activities with Nanobodies

Mohammed Akli Ayoub

Reproductive and Behavioural Physiology, Tours

Modulating GPCRs’ Biological Activities with Nanobodies



Annual meeting: 2015

Fields-Topics: P1 Molecular and Cellular

Type of talk: Fellows Speed Presentation

Modulating GPCRs’ Biological Activities with Nanobodies

Biography

I was born in Algeria and did my undergraduate and postgraduate studies in Biochemistry at the University of Paris XI. I obtained my PhD in 2003 from University Paris XI having carried out my research project at Cochin Institute (Paris). Then, I joined the Functional Genomics Institute in Montpellier for my first postdoctoral fellow from 2004 to 2009. In August 2009, I moved to Perth (Australia) where I was employed as full-time Research Assistant Professor by the University of Western Australia to work at Harry Perkins Institute of Medical Research. From 2012 to 2014, I have been appointed as Assistant Professor in the Biochemistry department in King Saud University (Saudi Arabia). In July 2014, I returned back to France as LE STUDIUM Loire Valley Institute for Advanced Studies and Marie-Curie/ AgreenSkills fellow to work at INRA-Val de Loire (Tours, France). Since January 2017, I am appointed as Assistant Professor in College of Science, Biology Department at United Arab Emirates University in Al Ain (UAE). My scientific career has two major focus: the biology of cell surface receptors and technology development based on BRET and FRET approaches applied to study different aspects of receptor function. During my career, I have published more than 50 publications with an average impact factor of 6 and having received in total more than 2500 citations.

Abstract

Modulating GPCRs’ Biological Activities with Nanobodies

My project aims to develop new generation of biologicals targeting GPCRs. These biologicals are antibody fragments generated from camelids, called nanobodies. I am in charge of developing a battery of molecular, biochemical, and signalling assays that will be instrumental for the development of the nanobodies. Indeed, nanobodies displaying distinct activation profiles are expected: activators versus inhibitors, full versus partial activities, competitors versus allosteric binders,… Each profile could potentially lead to valuable in vivo action; therefore accurate screening and characterization will be carried out. Furthermore, the potential clinical and agronomic applications of the nanobodies will be assessed using in vivo models.

The above presentations are protected under a Creative Commons non-commercial, non-derivative license (BY-NC-ND).

You are free to:
Share copy and redistribute the material in any medium or format.
Under the following terms:
Attribution You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial You may not use the material for commercial purposes.
NoDerivatives If you remix, transform, or build upon the material, you may not distribute the modified material.